Department of Radiation Oncology, Cancer Hospital of Tianjin Medical University, National Cancer Clinical Medical Research Center, Tianjin “Tumor Prevention and Control” Key Laboratory, Tianjin Malignant Tumor Clinical Medicine Research Center, Tianjin 300060, China
Abstract：Objective To compare the incidence of radiation pneumonitis (RP) between lung cancer patients from the European, American and Asian regions. Methods The studies related to lung cancer and RP were searched from PubMed, Embase, and Cochrane library. According to the different places where the studies were conducted, the searched studies were divided into two types:Asian studies and European, American and Australian studies. The incidence of RP between two regions was summarized. Studies related to dosimetry parameters were searched from PubMed database. Results A total of 3,190 patients from 14studies were included. Meta-analysis results showed that the incidence of ≥ grade 3 RP was similar in patients from Asia and Europe, America and Australia (4.9% vs. 4.6%, P=0.895), whereas the incidence of grade 5 RP in Asia was significantly higher than that in Europe, America and Australia (1.5% vs. 0.2%, P=0.002). Moreover, the lung irradiation dose received by the patients in the Asian group was relatively low. Lung V20Gy dose limitation standard was reported in 21studies. Further analysis found no statistical significance in lung V20Gy dose limitation standard between two regions (P=0.440), and the standard in Asian studies is likely to be even stricter. Conclusions The incidence of RP after chemoradiotherapy in lung cancer patients in Asia is relatively higher compared with those in Europe, America and Australia. The differences in dose limitation standard should be noted when the thoracic radiation regimen based solely on the data from foreign studies is applied to the patients in Asia.
Wei Jia,Zhang Zhen,Yu Jiaqi et al. Meta-analysis of the incidence of radiation pneumonitis between European,American and Asian populations[J]. Chinese Journal of Radiation Oncology, 2021, 30(6): 556-562.
[1] Dang J, Li G, Zang S, et al. Risk and predictors for early radiation pneumonitis in patients with stage Ⅲ non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy[J]. Radiat Oncol, 2014, 9:172. DOI:10.1186/1748-717X-9-172. [2] Vansteenkiste J, Naidoo J, Faivre-Finn C, et al. MA05.02 PACIFIC subgroup analysis:pneumonitis in Stage Ⅲ, unresectable NSCLC patients treated with durvalumab vs. placebo after CRT[J]. J Thorac Oncol, 2018, 13(10):S370-S371.DOI:10.1016/j.jtho.2018.08.350. [3] Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version5.1.0[DB/OL][2020-11-10]. http://www.cochrane-handbook.org.2011. [4] Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses[DB/OL][2020-11-10]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. 2012. [5] Beijer U, Wolf A, Fazel S. Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people:a systematic review and meta-analysis[J]. Lancet Infect Dis, 2012, 12(11):859-870.DOI:10.1016/S1473-3099(12)70177-9. [6] Hanna N, Neubauer M, Yiannoutsos C, et al. Phase Ⅲ study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage Ⅲ non-small-cell lung cancer:the Hoosier Oncology Group and U. S. Oncology[J]. J Clin Oncol, 2008, 26(35):5755-5760.DOI:10.1200/JCO.2008.17.7840. [7] Sun Z, Li Q, Li Z, et al. Clinical analysis of concurrent chemoradiotherapy in 83 patients with locally advanced non-small cell lung cancer[J]. Chin-German J Clin Oncol, 2012, 11(1):1-5. DOI:10.1007/s10330-011-0892-6. [8] Liew MS, Sia J, Starmans MH, et al. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage Ⅲ non-small cell lung cancer[J]. Cancer Med, 2013, 2(6):916-924.DOI:10.1002/cam4.142. [9] Liu L, Bi N, Ji Z, et al. Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy—retrospective analysis of 203 cases[J]. BMC Cancer, 2015, 15(1):715. DOI:10.1186/s12885-015-1710-2. [10] Landau DB, Hughes L, Baker A, et al. IDEAL-CRT:a phase 1/2 trial of isotoxic dose-escalated radiation therapy and concurrent chemotherapy in patients with stage Ⅱ/Ⅲ non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2016, 95(5):1367-1377.DOI:10.1016/j.ijrobp.2016.03.031. [11] Trinh H, Pinkham MB, Lehman M, et al. Outcomes treating stage Ⅲ non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy[J]. Clin Respir J, 2016, 10(4):428-434.DOI:10.1111/crj.12233. [12] Wang L, Wu YL, Lu S, et al. An East Asian subgroup analysis of PROCLAIM, a phase Ⅲ trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer[J]. Asia Pac J Clin Oncol, 2016, 12(4):380-387.DOI:10.1111/ajco.12513. [13] Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer:a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial[J]. J Clin Oncol, 2017, 35(1):56-62. DOI:10.1200/JCO.2016.69.1378. [14] Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT):an open-label, phase 3, randomised, superiority trial[J]. Lancet Oncol, 2017, 18(8):1116-1125. DOI:10.1016/S1470-2045(17)30318-2. [15] Sasaki T, Seto T, Yamanaka T, et al. A randomised phase Ⅱ trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer:WJOG5008L[J]. Br J Cancer, 2018, 119(6):675-682. DOI:10.1038/s41416-018-0243-2. [16] Isla D, De Las PeñasR, Insa A, et al. Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage Ⅲ non-small cell lung cancer:A randomized phase Ⅱ(RENO study)[J]. Lung Cancer, 2019, 135(161-168). DOI:10.1016/j.lungcan.2018.11.041. [17] Topkan E, Ozdemir Y, Kucuk A, et al. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage ⅢB/C non-small-cell lung carcinoma patients:Analysis of 956 patients[J]. PLoS One, 2019, 14(7):e0218627.DOI:10.1371/journal.pone.0218627. [18] Niho S, Yoshida T, Akimoto T, et al. Randomized phase Ⅱ study of chemoradiotherapy with cisplatin+ S-1 versus cisplatin+ pemetrexed for locally advanced non-squamous non-small cell lung cancer:SPECTRA study[J]. Lung Cancer, 2020, 141:64-71.DOI:10.1016/j.lungcan.2020.01.008. [19] Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer[J]. Int J Radiat Oncol Biol Phys, 2003, 55(1):110-115. DOI:10.1016/s0360-3016(02)03807-5. [20] Alharbi M, Janssen S, Golpon H, et al. Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage Ⅲ non-small cell cancer patients[J]. Radiat Oncol, 2017, 12(1):165. DOI:10.1186/s13014-017-0898-5. [21] Colaco RJ, Huh S, Nichols R C, et al. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer[J]. Acta Oncol, 2013, 52(3):506-513.DOI:10.3109/0284186X.2013.769063. [22] Hallqvist A, Bergström S, Björkestrand H, et al. Dose escalation to 84Gy with concurrent chemotherapy in stage Ⅲ NSCLC appears excessively toxic:Results from a prematurely terminated randomized phase Ⅱ trial[J]. Lung Cancer, 2018, 122(180-186). DOI:10.1016/j.lungcan.2018.06.020. [23] Jabbour SK, Berman AT, Decker RH, et al. Phase 1 trial of pembrolizumab aDministered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer:a nonrandomized controlled trial[J]. JAMA Oncol, 2020, 6(6):848-855. DOI:10.1001/jamaoncol.2019.6731. [24] Komaki R, Lee JS, Milas L, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer:report of a randomized comparative trial[J]. Int J Radiat Oncol Biol Phys, 2004, 58(5):1369-1377.DOI:10.1016/j.ijrobp.2003.10.005. [25] Phernambucq ECJ, Spoelstra FOB, Verbakel W, et al. Outcomes of concurrent chemoradiotherapy in patients with stage Ⅲ non-small-cell lung cancer and significant comorbidity[J]. Ann Oncol, 2011, 22(1):132-138. DOI:10.1093/annonc/mdq316. [26] Rengan R, Mick R, Pryma D, et al. A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage ⅢA/ⅢB non-small cell lung cancer:a report of toxicities and clinical response[J]. J Thorac Oncol, 2012, 7(4):709-715. DOI:10.1097/JTO.0b013e3182435aa6. [27] Torre-Bouscoulet L, Muñoz-Montaño WR, Martínez-Briseño D, et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer[J]. Respir Res, 2018, 19(1):72. DOI:10.1186/s12931-018-0775-2. [28] Wiersma TG, Dahele M, Verbakel WF, et al. Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer[J]. Lung Cancer, 2013, 80(1):62-67.DOI:10.1016/j.lungcan.2013.01.006. [29] Fukui T, Hosotani S, Soda I, et al. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab[J]. Thorac Cancer, 2020, 11(4):1005-1014.DOI:10.1111/1759-7714.13357. [30] Hasegawa T, Futamura Y, Horiba A, et al. A phase Ⅱ study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer[J]. J Radiat Res, 2016, 57(1):50-54.DOI:10.1093/jrr/rrv062. [31] Lee YH, Choi HS, Jeong H, et al. Neutrophil-lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy[J]. Clin Respir J, 2018, 12(3):1264-1273.DOI:10.1111/crj.12660. [32] Saito S, Abe T, Kobayashi N, et al. Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer[J]. Clin Transl Radiat Oncol, 2020, 23(85-88). DOI:10.1016/j.ctro.2020.05.006. [33] Song CH, Pyo H, Moon SH, et al. Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy[J]. Int J Radiat Oncol Biol Phys, 2010, 78(3):651-658. DOI:10.1016/j.ijrobp.2009.08.068. [34] Taira T, Yoh K, Nagase S, et al. Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer[J]. Cancer Chemother Pharmacol, 2018, 81(3):565-572. DOI:10.1007/s00280-018-3530-y. [35] Tsujino K, Hashimoto T, Shimada T, et al. Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer[J]. J Thorac Oncol, 2014, 9(7):983-990.DOI:10.1097/jto.0000000000000187. [36] Yuan S, Sun X, Li M, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage Ⅲ nonsmall cell lung cancer[J]. Am J Clin Oncol, 2007, 30(3):239-244.DOI:10.1097/01.coc.0000256691.27796.24. [37] Zhang X, Shin YK, Zheng Z, et al. Risk of radiation-induced pneumonitis after helical and static-port tomotherapy in lung cancer patients and experimental rats[J]. Radiat Oncol, 2015, 10:195. DOI:10.1186/s13014-015-0502-9. [38] Zhou Y, Yan T, Zhou X, et al. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy:Impact of pre-treatment pulmonary function parameters[J]. Strahlenther Onkol, 2020, 196(6):505-514.DOI:10.1007/s00066-019-01552-4.
2021, Vol. 30 
